Colorectal Cancer

Latest News

Blood test | Image credit: angellodeco - stock.adobe.com
Net Results Vary When Using Cell-Free DNA Blood Tests for CRC Screening

October 29th 2024

Results could vary between having a net benefit or harm based on the balance between achieving screening in individuals who otherwise wouldn’t and using cell-free DNA blood tests in favor of more effective methods of screening for colorectal cancer (CRC).

Robot-assisted surgery | Image credit: Monopoly919 - stock.adobe.com
Robotic Systems Possess Positive Outcomes, Safety in Colorectal Surgery

October 25th 2024

Fecal immunochemical test | Image credit: Paul Maguire - stock.adobe.com
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines

October 22nd 2024

Calculating cost | Image credit: joyfotoliakid - stock.adobe.com
Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment

October 10th 2024

Colorectal cancer | Image credit: Dr_Microbe - stock.adobe.com
CRC Screening Increases in Patients Aged 45 to 49 After USPSTF Recommendation

October 7th 2024

More News

Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib
September 26th 2023

Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib

Julia Bonavitacola
Although nofazinlimab was well tolerated and showed antitumor activity in many tumor types, no response was found when combined with regorafenib to treat metastatic colorectal cancer (mCRC).
Unmeasured Social Context Could Explain Racial Differences in Screening for CRC
September 19th 2023

Unmeasured Social Context Could Explain Racial Differences in Screening for CRC

Julia Bonavitacola
Screening for colorectal cancer (CRC) is defined by racial differences, which could be explained through social context.
Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years
September 18th 2023

Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years

Julia Bonavitacola
Although mortality and disability-adjusted life-years remained stable, the prevalence and incidence of early-onset colorectal cancer (CRC) increased globally in individuals aged 40 to 49 years.
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC
September 15th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

Caroline Seymour
The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.
Man waist measured
September 7th 2023

Visceral Obesity Associated With Anastomotic Leakage After Colon Cancer Surgery

Julia Bonavitacola
A significant relationship between visceral obesity and anastomotic leakage was found, which indicates that visceral obesity could be a risk factor in surgery for colon cancer.
tumor cell
September 4th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

Kyle Doherty
Circulating tumor DNA (ctDNA) status at the time of postoperative minimal residual disease assessment is a prognostic factor for disease-free survival (DFS) in patients with radically resected stage II to IV colorectal cancer (CRC).
Illustrated colorectal image | Credit: mi_viri - stock.adobe.com
August 28th 2023

HER2 Amplification Shows Prognostic Capabilities in mCRC

Megan Hollasch
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Doctor projects the human large intestine on the tablet. Study and analysis of colon cancer, bacteria, inflammation, ulcerative colitis, colonoscopy, diverticulosis. Health technology development: © Tom - stock.adobe.com
August 25th 2023

Personalized CRC Screening Remains Elusive, Requires Careful Planning

Maggie L. Shaw
Three sessions of a semi-structured focus group were conducted to gain patient feedback on personalized screening for colorectal cancer (CRC).
paper people of different colors
August 18th 2023

Time to Treatment Initiation Affected by Demographics, Socioeconomics in CRC, NSCLC

Kyle Doherty
Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.
AJMC
August 16th 2023

Social Determinants of Health: Are Colonoscopies Always Fit for Duty?

Benjamin K. Stone, MSc Jonathan I. Gates, MD Kristina A. Monteiro, PhD
Social determinants of health are associated with colonoscopy noncompletion in a Medicaid patient population at the Providence Community Health Centers.
black doctor speaking to older white male patient
August 10th 2023

Increases in Cancer Screenings, Chronic Condition Diagnoses in First Year of Medicare Coverage

Laura Joszt, MA
Patients were twice as likely to get a colorectal cancer screening and 50% more likely to get a breast cancer screening in their first year of Medicare coverage.
rendering of the colon above doctor's hands
August 3rd 2023

Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults

Laura Joszt, MA
Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
FDA approved red stamp on white background
August 2nd 2023

FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Kristi Rosa
The FDA approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who had previously been treated based on data from the phase 3 SUNLIGHT trial.
AJMC
July 27th 2023

A “Sludge Audit” for Health System Colorectal Cancer Screening Services

Michelle S. Rockwell, PhD, RD Mary C. Frazier, BS Jeffrey S. Stein, PhD Kimberly A. Dulaney, MD Sarah H. Parker, PhD George C. Davis, PhD John A. Rockwell, MS, MBA Benjamin L. Castleman, EdD Cass R. Sunstein, JD John W. Epling, MD, MSEd
A systematic, mixed methods “sludge audit” identified novel health system delivery targets for improving colorectal cancer screening services.
image of cancer cells
January 23rd 2023

Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer

Allison Inserro
Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as well as royalties on worldwide net sales, with the exception of mainland China, Hong Kong, and Macau.
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
January 19th 2023

Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC

Mary Caffrey
The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
image of genes
December 22nd 2022

Large Genome-Wide Association Study Finds Possible New Colorectal Cancer Targets

Pearl Steinzor
A recent genome-wide association study found hundreds of genes linked to risk for colorectal cancer among a diverse worldwide population.
Evidence-Based Oncology logo
December 2nd 2022

From Cancer Prevention to Treatment: Underpinning the Advances, Challenges to Democratizing Precision Oncology

Matthew Gavidia
Coverage from the Institute for Value-Based Medicine® event in Nashville, Tennessee, held November 17, 2022. The event was held in partnership with Vanderbilt-Ingram Cancer Center.
What Does PD-L2 Tell Us About Advanced Colorectal Cancer?
December 30th 2020

What Does PD-L2 Tell Us About Advanced Colorectal Cancer?

Mary Caffrey
Results show the presence of PD-L2 in the tumor may be an independent predictor of survival outcomes for patients with advanced stage colon carcinoma.
obesity
December 30th 2020

Results Identify Sex-Specific Links Between Adiposity and CRC, but Much Still Unknown

Mary Caffrey
The connection between obesity and colorectal cancer is well established, but the mechanics are not understood.
NCI-Funded Study Finds Triple Therapy Packs a Punch in Metastic Colorectal Cancer
December 24th 2020

NCI-Funded Study Finds Triple Therapy Packs a Punch in Metastic Colorectal Cancer

AJMC Staff
Adding vemurafenib, known to target a mutation affecting 10% of metastatic colorectal cancers, made a big difference.
Study Probes Links Between Mutations, Metastasis in mCRC in China
December 23rd 2020

Study Probes Links Between Mutations, Metastasis in mCRC in China

Allison Inserro
Researchers sought to gain a better understanding of the relationship between genetic mutations in metastatic colon cancer (mCRC), advanced disease, and locations of primary tumors.
Guidance Describes Management of Malignant Colorectal Polyps
December 23rd 2020

Guidance Describes Management of Malignant Colorectal Polyps

Skylar Jeremias
Early detection of colon cancer is key to survival. New guidance advises endoscopists in identifying malignant colorectal polyps and recommendations for surgery.
Medicaid Expansion May Result in Earlier Colon Cancer Diagnosis, Study Says
December 13th 2020

Medicaid Expansion May Result in Earlier Colon Cancer Diagnosis, Study Says

AJMC Staff
The authors wrote that in states that expanded Medicaid health insurance coverage in 2014, there was an increase of early-stage colon cancer diagnoses compared with states that did not implement expansion.
AI Helps Determine Which Patients Benefit Most From Colorectal Cancer Treatment
December 9th 2020

AI Helps Determine Which Patients Benefit Most From Colorectal Cancer Treatment

Gianna Melillo
Researchers found the application of FOLFOXai, an artificial intelligence (AI)–based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer (mCRC), may lead to improved treatment outcomes for some patients with mCRC and other cancers.
Site Logo
November 12th 2020

Impact of Travel Distance on Quality Outcomes in Colorectal Cancer

Aaron C. Spaulding, PhD Shalmali Borkar, MBBS, MPH Osayande Osagiede, MBBS, MPH Jordan J. Cochuyt, BS Riccardo Lemini, MD Nolan Otto, BS Dorin T. Colibaseanu, MD
This study identified characteristics of patients with colorectal cancer who traveled farther for surgery and found that those who traveled tended to stay longer at the hospital.
Biomarker Use in Colorectal Cancer
December 18th 2019

Biomarker Use in Colorectal Cancer

Maggie L. Shaw
Despite a 20% drop in mortality since 2009, colorectal cancer accounted for 9.8% (881,000) of deaths worldwide in 2018 and represents 10.2% of all cancer cases worldwide. It is No. 3 on the list of most prevalent cancers worldwide—1.8 million new cases in 2018—behind only lung cancer and breast cancer.
NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations
April 7th 2019

NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations

Laura Joszt, MA
Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo